Review of NICE Technology Appraisal Guidance no. 47 (sections 1.7 and 1.8); glycoprotein IIb/IIIa inhibitors for the treatment of acute coronary syndromes

Proposal to move guidance to the static list

As you may be aware the planned date for review of the above guidance was March 2010.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Having re-looked at the guidance and the possible scope for updating the guidance, we would like to inform you that part of the guidance has been dealt with within the context of a clinical guideline.

Recommendations 1.1 – 1.6 of original guidance have been updated by the on-going NICE guideline on ‘Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction’ published in March 2010.

Having re-run the search strategy from the original assessment report the Institute has not found any relevant additions to the evidence base that would have a material effect on the remaining Technology Appraisal recommendations of 1.7 and 1.8. The newly identified evidence is not likely to change the current guidance recommendations. Consequently, we propose that the original guidance should be transferred to the static list.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted.

Please note all comments received will be published on the Institute’s website when a decision has been made.

May 2010 

• Provisional matrix of stakeholders
• Proposal paper presented to the Institute’s Guidance Executive